Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could Low-Oxygen breathing supercharge gait therapy for MS?

NCT ID NCT07631923

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether breathing low-oxygen air for short periods right before walking training helps people with multiple sclerosis walk better and farther. Thirty-five participants will receive either the low-oxygen breathing or a sham (placebo) version, followed by treadmill or overground gait training. The goal is to see if this combination improves walking speed and endurance more than training alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Acute Intermittent Hypoxia (AIH) – brief sessions of breathing air with low oxygen
What this could lead to
If it works, this could point toward a non-drug way to improve walking and endurance in people with multiple sclerosis.
What could go wrong
This is a small, early-stage trial with only 35 participants. The breathing intervention is experimental and may not produce meaningful or lasting improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of clinically definite multiple sclerosis * Patient-Determined Disease Steps (PDDS) score between 3 and 6 * Relapse-free for at least 6 months prior to enrollment * Age ≥ 18 years and ≤ 75 years * Resting oxygen saturation (SpO₂) ≥ 95% on room air * Systolic blood pressure between 85-140 mmHg and diastolic blood pressure between 55-90 mmHg * Modified Ashworth Scale (MAS) score ≤ 3 at the ankle and knee * Mini-Mental State Examination (MMSE) score ≥ 24 * Ability to walk at least 10 meters with or without an assistive device * Ability to perform active ankle dorsiflexion and plantarflexion Exclusion Criteria: * Uncontrolled hypertension or hypotension outside the required ranges * History of epilepsy or seizures * Uncontrolled pulmonary, cardiovascular, or orthopedic disease * Premorbid or ongoing major psychiatric illness (e.g., major depression, psychosis) * Other neurological disease (e.g., stroke, traumatic brain injury, peripheral neuropathy) * Illnesses with potential to cause brain injury * Frequent or severe unexplained headaches * Pregnancy * Implanted medical devices (e.g., pacemakers, intrathecal pumps, brain stimulators)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.